Table 2.
Comparison between hospital survivors and nonsurvivorsa
| Patient demographics, N = 102 (100%) | Hospital survivors (n = 78) | Hospital nonsurvivors (n = 24) | P value b | OR (95% CI) c |
|---|---|---|---|---|
| Women, n (%) | 24 (30.8) | 13 (54.2) | 0.05 | 2.7 (0.97 to 6.8) |
| Median age, yr (IQR) | 62 (47 to 77) | 69 (58 to 80) | 0.13 | |
| From admission to awakening (day 1) | ||||
| Mean blood glucosed, mM/l (IQR) | 7.6 (6.8 to 8.6) | 8.3 (7.2 to 9.7) | 0.07 | 1.2 (0.95 to 1.4) |
| Women | 8.0 (7.0 to 8.7) | 9.4 (7.8 to 11.1) | 0.03 | 1.5 (0.98 to 2.2) |
| Men | 7.4 (6.7 to 8.6) | 7.2 (6.7 to 8.7) | 0.89 | |
| At awakening (day 1) | ||||
| Median SAPS II (IQR) | 28 (21 to 34) | 35 (29 to 41) | 0.007 | 1.1 (1.0 to 1.1) |
| Median FSHe, mIU/ml (IQR) | ||||
| Women | 2.9 (0.75 to 17.9) | 1.6 (0.68 to 4.7) | 0.41 | |
| Men | 3.9 (1.9 to 7.6) | 3.8 (1.6 to 6.5) | 0.93 | |
| Median LHe, mIU/ml (IQR) | ||||
| Women | 0.35 (0.2 to 3.0) | 0.21 (0.21 to 1.2) | 0.61 | |
| Men | 4.35 (2.2 to 6.5) | 6.9 (0.63 to 13) | 0.56 | |
| Median prolactin, ng/ml (IQR) | 9.5 (5.2 to 16) | 8.3 (5.1 to 15) | 0.54 | |
| Median estradiole, pg/ml (IQR) | ||||
| Women | 10 (10 to 28) | 10 (10 to 12) | 0.82 | |
| Men | 14.5 (10 to 23) | 10 (10 to 24) | 0.79 | |
| Median testosteronee, ng/ml (IQR) | ||||
| Women | 0.09 (0.07 to 0.18) | 0.07 (0.07 to 0.16) | 0.81 | |
| Men | 0.78 (0.35 to 1.70) | 0.63 (0.43 to 1.1) | 0.57 | |
| Median cortisolf, ng/ml (IQR) | 16.0 (12.0 to 23.0) | 23.0 (18.5 to 34.5) | 0.01 | 4.3 (1.5 to 12.1) |
| Women | 15.5 (12.0 to 25.0) | 23.0 (20.0 to 25.0) | ||
| Men | 16.0 (12.0 to 23.0) | 22.0 (14.0 to 41.5) | ||
| Median DHEAe, ng/ml (IQR) | ||||
| Women | 0.30 (0.30 to 0.66) | 0.30 (0.30 to 0.89) | 0.50 | |
| Men | 0.59 (0.30 to 1.80) | 0.30 (0.30 to 0.45) | 0.01 | 0.2 (0.04 to 0.97) |
| Median DHEASe, ng/ml (IQR) | ||||
| Women | 262 (107 to 469) | 366 (79 to 580) | 0.86 | |
| Men | 486 (184 to 1,141) | 198 (100 to 310) | 0.04 | 0.2 (0.03 to 0.8) |
| Median progesterone, ng/ml (IQR) | ||||
| Women | 0.23 (0.05 to 0.29) | 0.24 (0.04 to 0.69) | 0.49 | |
| Median SH (%) | 57 (73%) | 18 (75%) | 1.00 | |
| Median PH (%) | ||||
| Men | 19 (35%) | 6 (55%) | 0.31 | |
| Median TSH, mIU/ml (IQR) | 1.25 (0.52 to 2.35) | 1.34 (0.74 to 2.12) | 0.68 | |
| Median IGF-1, ng/ml (IQR) | 78 (56 to 112) | 65 (46 to 70) | 0.007 | 0.2 (0.07 to 0.6) |
| Women | 73.5 (50.5 to 113.5) | 59.5 (57.5 to 69.0) | ||
| Men | 81 (59 to 111) | 65.0 (50.0 to 73.0) |
aSAPS, Simplified Acute Physiology Score II [15]; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulfate; FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating hormone; IGF-1, insulin-like growth factor 1; SH secondary hypogonadism; PH, primary hypogonadism; IQR, interquartile range; OR, odds ratio; 95% CI, 95% confidence interval; bP values were derived from performing the Mann-Whitney U test or Fisher's exact test as appropriate; cOR and 95% CI were estimated by using exact logistic regression models; dORs estimated after dichotomization on median value; eassessed in 85 patients, including 56 men and 29 postmenopausal women, among whom 11 men and 11 women died in the hospital, respectively; fplasma cortisol levels of 83 patients were taken into account in the analysis; the other 19 patients were still being treated with hydrocortisone at the time the blood sample was taken and thus were excluded from the cortisol measurement.